Torrent & Cadila Pharmaceuticals get license to manufacture oral antiviral Covid-19 pill nirmatrelvir

Torrent said that t it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with MPP. Cadila said that it will cater to Indian and export markets since many countries with high Covid-19 burden lack access to effective therapy.